The short version
10 companies supply this market — deep enough that no single failure threatens the supply.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Cambia
diclofenac potassium · DICLOFENAC POTASSIUM 50 mg/1 · Powder, For Solution · Oral · Assertio Therapeutics, Inc.
NDC 13913-0012-02 · 9 PACKET in 1 CARTON / 1 POWDER, FOR SOLUTION in 1 PACKET · NDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 31722-0046-32) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$20.94per unit
middle half $19.83–$47.81 · 23 plans · Apr 1, 2026
Est. net of rebatesⓘ
$12.57–$15.71
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
0%of plans cover it
tier 3 · prior auth 0% · step therapy 65% · qty limit 100%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for diclofenac potassium (other) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $1,221.23 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA022165
- TE code
- AB
- Approval date
- Jun 17, 2009
- Patents / exclusivity
- 4 patents, 0 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| patent | 8097651 | Jun 16, 2026 |
| patent | 7759394 | Jun 16, 2026 |
| patent | 8927604 | Jun 16, 2026 |
| patent | 9827197 | Jun 16, 2026 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of diclofenac potassium (Powder, For Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Par Health USA, LLC | DICLOFENAC POTASSIUM 50 mg/1 | Aug 6, 2026 | Sep 3, 2026 |
| Sun Pharmaceutical Industries, Inc. | DICLOFENAC POTASSIUM 50 mg/1 | Jul 16, 2026 | Sep 3, 2026 |
| Ascend Laboratories, LLC | DICLOFENAC POTASSIUM 50 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Assertio Therapeutics, Inc. | DICLOFENAC POTASSIUM 50 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Camber Pharmaceuticals, Inc. | DICLOFENAC POTASSIUM 50 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Leading Pharma, LLC | DICLOFENAC POTASSIUM 50 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Nivagen Pharmaceuticals, Inc. | DICLOFENAC POTASSIUM 50 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Torrent Pharmaceuticals Limited | DICLOFENAC POTASSIUM 50 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Umedica Laboratories USA Inc. | DICLOFENAC POTASSIUM 50 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Endo USA, Inc. | DICLOFENAC POTASSIUM 50 mg/1 | Jul 15, 2026 | Aug 5, 2026 |
| Taro Pharmaceuticals U.S.A., Inc. | DICLOFENAC POTASSIUM 50 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Cambia — NDC 13913-0012-02," retrieved September 3, 2026, https://drugdashboards.com/drug/13913001202.
Free to cite with attribution — see how the data is put together.